Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.19) by 41.36 percent. This is a 3.57 percent increase over losses of $(0.28) per share from the same period last year.